Stockreport

Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Innate Pharma S.A. - American Depositary Shares  (IPHA) 
PDF IPH45 is a novel and differentiated exatecan-Antibody Drug Conjugate targeting Nectin-4In PDX models of urothelial tumors, IPH45 has stronger activity than approved Nect [Read more]